ATE509279T1 - Verfahren zur überprüfung und kontrolle des milchsäurefermentationsprozesses/stoffwechselpf devon aerober glukosefermentation in säugerorganismen - Google Patents

Verfahren zur überprüfung und kontrolle des milchsäurefermentationsprozesses/stoffwechselpf devon aerober glukosefermentation in säugerorganismen

Info

Publication number
ATE509279T1
ATE509279T1 AT06723195T AT06723195T ATE509279T1 AT E509279 T1 ATE509279 T1 AT E509279T1 AT 06723195 T AT06723195 T AT 06723195T AT 06723195 T AT06723195 T AT 06723195T AT E509279 T1 ATE509279 T1 AT E509279T1
Authority
AT
Austria
Prior art keywords
agf
mam
individual
devon
metabolism
Prior art date
Application number
AT06723195T
Other languages
English (en)
Inventor
Johannes Coy
Original Assignee
Coy Johannes Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05004930A external-priority patent/EP1701165A1/de
Application filed by Coy Johannes Dr filed Critical Coy Johannes Dr
Application granted granted Critical
Publication of ATE509279T1 publication Critical patent/ATE509279T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
AT06723195T 2005-03-07 2006-03-03 Verfahren zur überprüfung und kontrolle des milchsäurefermentationsprozesses/stoffwechselpf devon aerober glukosefermentation in säugerorganismen ATE509279T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05004930A EP1701165A1 (de) 2005-03-07 2005-03-07 Therapeutischer und diagnostischer Gebrauch von TKTL1 sowie seiner Inhibitoren und Aktivatoren
EP05013170 2005-06-17
PCT/EP2006/001951 WO2006094716A1 (en) 2005-03-07 2006-03-03 Method for ckecking and controlling the mammalian lactic acid fermentation process/aerobic glucose fermentation metabolic pathway in mammalian organism

Publications (1)

Publication Number Publication Date
ATE509279T1 true ATE509279T1 (de) 2011-05-15

Family

ID=36224891

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06723195T ATE509279T1 (de) 2005-03-07 2006-03-03 Verfahren zur überprüfung und kontrolle des milchsäurefermentationsprozesses/stoffwechselpf devon aerober glukosefermentation in säugerorganismen

Country Status (11)

Country Link
US (3) US7754437B2 (de)
EP (2) EP2256500B1 (de)
JP (1) JP5095600B2 (de)
AT (1) ATE509279T1 (de)
AU (1) AU2006222277B2 (de)
CA (1) CA2600206C (de)
DK (2) DK1856537T3 (de)
ES (1) ES2480416T3 (de)
PL (2) PL2256500T3 (de)
PT (1) PT2256500E (de)
WO (1) WO2006094716A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007013903A1 (de) 2007-03-20 2008-09-25 Coy, Johannes F., Dr. Getränk
DE102010007243B4 (de) * 2010-02-09 2011-11-17 Frank Kischkel Therapieoptimierung bei Krebspatienten durch Austesten von Therapiekombinationen mittels in vitro Testungen (Zusatz)
DE102011008016A1 (de) * 2011-01-06 2012-07-12 Johannes F. Coy Schokoladenmasse
DE102020116980A1 (de) * 2020-06-27 2021-12-30 TAVARGENIX GmbH Verwendung von Co-Enzym-Antagonisten zur Stoffwechselverlangsamung
CN112730734A (zh) * 2020-12-22 2021-04-30 河南星汉生物科技有限公司 一种葡萄糖发酵乳酸中发酵液残糖的检验方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006219A (en) * 1972-08-10 1977-02-01 Ceres Pharmacal Company Composition and method for countering effects of alcohol consumption
DE2834706A1 (de) * 1978-08-08 1980-02-14 Boehringer Mannheim Gmbh Verfahren und reagens zur bestimmung von glutamat-oxalacetat-transaminase und glutamat-pyruvat-transaminase
US4594237A (en) * 1984-04-16 1986-06-10 Walter Ziegler Method for testing chemical and biological substances
US6919185B2 (en) * 2000-05-31 2005-07-19 Bayer Aktiengesellschaft Regulation of human transketolase-like enzyme
US7381713B2 (en) * 2000-12-04 2008-06-03 Sioan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
EP1354961B1 (de) 2002-04-19 2008-01-23 Johannes Dr. Coy Zusammensetzungen und Verfahren zur Behandlung und zur Detektion von proliferativen Störungen die mit der Überexpression des menschlichen "Transketolase like-1" gens in Zusammenhang stehen

Also Published As

Publication number Publication date
CA2600206A1 (en) 2006-09-14
PT2256500E (pt) 2014-07-18
JP2008531065A (ja) 2008-08-14
DK2256500T3 (da) 2014-07-14
AU2006222277B2 (en) 2011-04-07
CA2600206C (en) 2011-01-04
PL1856537T3 (pl) 2011-10-31
US7754437B2 (en) 2010-07-13
PL2256500T3 (pl) 2014-10-31
DK1856537T3 (da) 2011-07-18
US20080095703A1 (en) 2008-04-24
EP1856537A1 (de) 2007-11-21
US20100240687A1 (en) 2010-09-23
US11236381B2 (en) 2022-02-01
AU2006222277A1 (en) 2006-09-14
US11359225B2 (en) 2022-06-14
EP2256500A2 (de) 2010-12-01
ES2480416T3 (es) 2014-07-28
JP5095600B2 (ja) 2012-12-12
EP2256500B1 (de) 2014-04-23
US20200248227A1 (en) 2020-08-06
WO2006094716A1 (en) 2006-09-14
EP1856537B1 (de) 2011-05-11
EP2256500A3 (de) 2012-08-29

Similar Documents

Publication Publication Date Title
WO2008064067A3 (en) Method for the sequential analysis of different components in a single biological sample and reagents therefor
WO2008133729A3 (en) Sequential analysis of biological samples with intermediate bleaching of fluorescence detector
WO2017153992A1 (en) Method and system for continuous biosensing
Rajan et al. Monitoring pH, temperature and humidity in long-term stem cell culture in CO 2 incubator
US9133501B2 (en) Analysis of direct factor Xa inhibitors
EP2662453A3 (de) Nachweis und Behandlung von Schizophrenie
Dietzsch et al. On-line multiple component analysis for efficient quantitative bioprocess development
US9944971B2 (en) Determination of direct thrombin inhibitors in fluids like serum or urine
PT2256500E (pt) Utilização de inibidores da enzima tktl1
GB2593360A (en) Antimicrobial susceptibility assay and kit
Cui et al. High-throughput and specific detection of microorganisms by intelligent modular fluorescent photoelectric microbe detector
Waters et al. Rapid quantitative and qualitative analysis of biofilm production by Staphylococcus epidermidis under static growth conditions
CN201935910U (zh) 一种检测水质毒性的装置
CN104990913A (zh) 一种基于金纳米颗粒生长检测葡萄糖的方法
Lamboursain et al. A lab‐built respirometer for plant and animal cell culture
WO2023107879A1 (en) Method and apparatus for sterile and noninvasive measurements of substances in bioreactors and other sterile environments
CN101348823A (zh) 放射线剂量的生物检测用报告质粒的应用
CN110872607A (zh) 一种检测碱性磷酸酶的荧光生物传感器及其制备方法
JP2008531065A5 (de)
JP5021273B2 (ja) 老化度の判断方法
WO2009011277A1 (ja) 抗酸菌属細菌の検出および同定用オリゴヌクレオチド、およびその用途
He et al. An Enzyme Kinetics-Based Laboratory Module Aimed at Introducing Undergraduates to High-Throughput Drug Screening
EP4698906A1 (de) Verfahren zur messung von oxidativem stress
FI20040523A7 (fi) Menetelmä ja laite mikrobien kasvun toteamiseksi
Ye et al. Ex-Vivo Expansion and Differentiation of Haematopoietic Stem Cells (Hscs) Using on-Line Monitoring and Design of Experiments (DOE)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1856537

Country of ref document: EP